# Potentiality of LPS in Ameliorating the Histopathological Responses in Visceral Leishmaniasis‐Infected Mice

**Authors:** Ghusoon A. A. Al-Maphregy, Hazima mossa Alabassi, Ashwaq Ahmed Hussein

PMC · DOI: 10.1155/japr/8684617 · Journal of Parasitology Research · 2026-02-17

## TL;DR

This study explores how LPS, a bacterial compound, can reduce tissue damage in mice infected with visceral leishmaniasis, a severe parasitic disease.

## Contribution

The study demonstrates LPS's potential as a treatment for visceral leishmaniasis by showing its impact on immune cells and tissue health.

## Key findings

- LPS treatment significantly altered immune cell counts in infected mice, with notable changes in lymphocytes, neutrophils, and eosinophils.
- Low concentrations of LPS (20-60 ng/mL) improved liver and spleen histopathology in infected mice.
- High LPS concentrations (80 ng/mL) caused tissue damage, suggesting a concentration-dependent effect.

## Abstract

Visceral leishmaniasis is the second most fatal parasite illness worldwide, and it is the most severe type of leishmaniasis. LPS is a crucial chemical compound on the bacterial cell wall that the host recognizes and uses to launch an immune response to eliminate invasive infections.

Four concentrations of LPS were used to treat infected mice with visceral leishmaniasis (20, 40, 60, and 80 ng/mL). Differential cell count and phagocytic index tests were done, then the liver and spleen were separated, and a histopathological assay was performed.

The findings demonstrated that all blood cells, with the exception of basophils, varied significantly between the uninfected and infected groups. With the exception of the 40 ng/mL concentration, there were notable variations in lymphocytes between the treated and infected groups as well as across the treated groups. With the exception of the 60 ng/mL concentration, neutrophils and monocytes showed significant changes between the treated and infected groups. Eosinophils, however, showed noticeable differences between the infected group and the treated groups. As for the phagocytic index, there was a significant difference between the uninfected and treated groups with the infected group. Histopathological results showed the effectiveness of LPS in the treatment of infected liver and spleen, especially in low concentrations (20, 40, and 60 ng/mL), whereas the highest concentration of LPS showed significant damage to liver and spleen tissue.

This result opens up prospects for the possibility of using LPS as a treatment for many pathogens.

## Linked entities

- **Diseases:** visceral leishmaniasis (MONDO:0005445)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, CD14 (CD14 molecule) [NCBI Gene 929], Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, IRF6 (interferon regulatory factor 6) [NCBI Gene 3664] {aka LPS, OFC6, PIT, PPS, PPS1, VWS}
- **Diseases:** shock (MESH:D012769), inflammation (MESH:D007249), Leishmania infection (MESH:D007896), Cancer (MESH:D009369), OALs (MESH:C000719624), depletion (MESH:C536350), Kala-azar (MESH:D007898), fever (MESH:D005334), CL (MESH:D002971), death (MESH:D003643), Cytotoxicity (MESH:D064420), weight loss (MESH:D015431), hypertrophy (MESH:D006984), Infected (MESH:D007239), Infected Liver (MESH:D017093), bacterial infections (MESH:D001424), sepsis (MESH:D018805), tissue damage (MESH:D017695), hyperplasia (MESH:D006965), necrosis (MESH:D009336)
- **Chemicals:** formazan (MESH:D005562), Methanol (MESH:D000432), NaCl (MESH:D012965), Paraffin (MESH:D010232), streptomycin (MESH:D013307), wax (MESH:D014885), xylene (MESH:D014992), lipophosphoglycans (MESH:C008290), isoflurane (MESH:D007530), water (MESH:D014867), ethanol (MESH:D000431), Lipid A (MESH:D008050), gentamycin (MESH:D005839), glycolipid (MESH:D006017), penicillin (MESH:D010406), oligosaccharide (MESH:D009844), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MESH:C022616), NNN (-), MTT (MESH:C070243), LPS (MESH:D008070), Formaldehyde (MESH:D005557), DMSO (MESH:D004121), eosin (MESH:D004801)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Mus musculus (house mouse, species) [taxon 10090], Human immunodeficiency virus 1 (no rank) [taxon 11676], Phlebotominae (sand flies, subfamily) [taxon 7198], Homo sapiens (human, species) [taxon 9606], Oryza sativa (Asian cultivated rice, species) [taxon 4530], Fagopyrum esculentum (common buckwheat, species) [taxon 3617], Leishmania donovani (species) [taxon 5661]
- **Mutations:** C-26 C
- **Cell lines:** NHF — Homo sapiens (Human), Finite cell line (CVCL_ZM45), Balb — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0637)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12910174/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12910174/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12910174/full.md

---
Source: https://tomesphere.com/paper/PMC12910174